Potassium citrate

Description

Potassium citrate USP is a citrate salt of potassium with an empirical formula of K₃C₆H₅O₇ • H₂O. The extended-release formulation is presented as pale yellow colored, oral wax-matrix tablets. Each tablet contains either 5 mEq (540 mg), 10 mEq (1080 mg), or 15 mEq (1620 mg) of potassium citrate USP. Inactive ingredients in the formulation include carnauba wax, stearic acid, and magnesium stearate. The USP dissolution test for this product is currently pending.

Uses and Indications

Potassium citrate is indicated for the management of renal tubular acidosis (RTA) associated with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis, with or without the presence of calcium stones.

There are no teratogenic or nonteratogenic effects associated with the use of potassium citrate.

Dosage and Administration

For patients with severe hypocitraturia (urinary citrate < 150 mg/day), therapy should be initiated at a dosage of 60 mEq per day. This can be administered as 30 mEq two times per day or 20 mEq three times per day. Doses should be taken with meals, within 30 minutes after meals, or at bedtime.

In cases of mild to moderate hypocitraturia (urinary citrate > 150 mg/day), therapy should commence at a dosage of 30 mEq per day. This may be given as 15 mEq two times per day or 10 mEq three times per day, also with meals, within 30 minutes after meals, or at bedtime.

It is essential to adhere to these dosing schedules to optimize therapeutic outcomes.

Contraindications

Use of this product is contraindicated in the following situations:

Patients with hyperkalemia or conditions predisposing them to hyperkalemia, including chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, and extensive tissue breakdown.

Patients with gastrointestinal conditions that may cause arrest or delay in tablet passage, such as delayed gastric emptying, esophageal compression, intestinal obstruction, or stricture.

Patients with peptic ulcer disease.

Patients with an active urinary tract infection.

Patients with renal insufficiency, specifically those with a glomerular filtration rate of less than 0.7 ml/kg/min.

Warnings and Precautions

Patients receiving potassium citrate should be closely monitored for the development of hyperkalemia, particularly in those with compromised renal function or conditions that impair potassium excretion. Hyperkalemia can lead to serious complications, including cardiac arrest, and may occur rapidly and without symptoms. Therefore, the use of potassium citrate is contraindicated in individuals with chronic renal failure or severe myocardial damage, as well as in patients with heart failure.

In addition, healthcare professionals should be vigilant for gastrointestinal complications. If a patient experiences severe vomiting, abdominal pain, or gastrointestinal bleeding, potassium citrate must be discontinued immediately. In such cases, further evaluation is warranted to rule out serious conditions such as bowel perforation or obstruction.

Regular monitoring of potassium levels is recommended for patients at risk of hyperkalemia to ensure safe administration of potassium citrate.

Side Effects

Patients may experience a range of adverse reactions associated with potassium citrate administration. Common adverse reactions include minor gastrointestinal complaints such as abdominal discomfort, vomiting, diarrhea, loose bowel movements, and nausea.

Serious adverse reactions have been identified, notably hyperkalemia, which can occur in patients with impaired mechanisms for excreting potassium. This condition can lead to cardiac arrest and may develop rapidly, often without symptoms. In cases of severe vomiting, abdominal pain, or gastrointestinal bleeding, potassium citrate should be discontinued immediately, and the possibility of bowel perforation or obstruction should be investigated.

Additional considerations for adverse reactions include specific patient populations at increased risk. Patients with hyperkalemia or conditions predisposing them to hyperkalemia—such as chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, or extensive tissue breakdown—should be closely monitored. Furthermore, patients with delayed gastric emptying, esophageal compression, intestinal obstruction, or stricture may experience complications related to tablet passage through the gastrointestinal tract.

Other at-risk groups include patients with peptic ulcer disease, active urinary tract infections, and those with renal insufficiency, particularly those with a glomerular filtration rate of less than 0.7 ml/kg/min. Hyperkalemia is often asymptomatic and may only be detected through increased serum potassium concentrations and characteristic electrocardiographic changes, such as peaking of the T-wave, loss of the P-wave, depression of the S-T segment, and prolongation of the QT interval. Late manifestations of hyperkalemia can include muscle paralysis and cardiovascular collapse due to cardiac arrest.

Drug Interactions

Concomitant administration of potassium-sparing diuretics is contraindicated due to the potential for severe hyperkalemia. It is advised to avoid the use of these agents together.

Drugs that slow gastrointestinal transit time, including anticholinergics, may exacerbate gastrointestinal irritation when used with potassium salts. Caution is recommended when these medications are co-administered.

For patients receiving renin-angiotensin-aldosterone inhibitors, monitoring for hyperkalemia is essential. Regular assessment of potassium levels is advised to prevent complications.

Nonsteroidal anti-inflammatory drugs (NSAIDs) may also increase the risk of hyperkalemia. Patients should be monitored closely for elevated potassium levels when these medications are used concurrently.

Packaging & NDC

The table below lists all NDC Code configurations of Potassium Citrate, the U.S. brand-name prescription product. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established. Therefore, the use of this medication in children is not recommended until further data is available to support its use in this population.

Geriatric Use

Elderly patients may exhibit increased sensitivity to side effects and potential reductions in kidney function, necessitating caution when prescribing this medication. Although there are no specific dosage adjustments or recommendations for geriatric patients outlined in the prescribing information, healthcare providers should remain vigilant due to the general considerations associated with pharmacotherapy in older adults.

Particular attention should be given to the use of potassium citrate in elderly patients, especially those with chronic renal failure or conditions that impair potassium excretion, such as severe myocardial damage or heart failure. The avoidance of this medication in such populations is critical to prevent adverse effects.

Regular monitoring of serum electrolytes, serum creatinine, and complete blood counts is recommended every four months, with increased frequency for patients who have cardiac disease, renal disease, or acidosis. This monitoring is especially important for elderly patients, who may be at a heightened risk for complications.

Elderly patients may also have impaired mechanisms for excreting potassium, which can lead to hyperkalemia and potentially life-threatening cardiac arrest. Therefore, careful observation for signs of hyperkalemia is essential in this demographic to ensure patient safety and effective management of their health conditions.

Pregnancy

Pregnant patients should be aware that animal reproduction studies have not been conducted with potassium citrate. Therefore, it is not known whether potassium citrate can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. Given the lack of data, potassium citrate should be prescribed to pregnant women only if clearly needed, weighing the potential benefits against any unknown risks. Healthcare professionals are advised to exercise caution and consider alternative treatments when appropriate.

Lactation

The normal potassium ion content of human milk is approximately 13 mEq/L. It is currently unknown whether potassium citrate affects this potassium content in breast milk. Therefore, potassium citrate should be administered to lactating mothers only if it is clearly needed.

Renal Impairment

Patients with renal impairment may experience hyperkalemia due to impaired mechanisms for excreting potassium. The administration of potassium citrate in these individuals can lead to hyperkalemia and potentially cardiac arrest. It is important to note that hyperkalemia can develop rapidly and may be asymptomatic. Therefore, the use of potassium citrate should be avoided in patients with chronic renal failure or any other conditions that impair potassium excretion, such as severe myocardial damage or heart failure.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there is no information available regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population.

Overdosage

The administration of potassium salts in individuals without predisposing conditions for hyperkalemia is unlikely to result in serious hyperkalemia when dosages are kept within recommended limits. However, it is crucial to recognize that hyperkalemia often presents asymptomatically, typically indicated only by elevated serum potassium levels and specific electrocardiographic changes. These changes may include T-wave peaking, loss of the P-wave, S-T segment depression, and QT interval prolongation. In advanced cases, late manifestations can occur, such as muscle paralysis and cardiovascular collapse due to cardiac arrest.

Management of Hyperkalemia

In the event of hyperkalemia, several treatment measures should be implemented:

• Patients must be closely monitored for arrhythmias and electrolyte imbalances.

• It is essential to discontinue any medications that contain potassium or possess potassium-sparing properties. This includes potassium-sparing diuretics, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and certain nutritional supplements.

• Dietary sources high in potassium should also be eliminated. Foods such as almonds, apricots, bananas, various beans (lima, pinto, white), cantaloupe, canned carrot juice, figs, grapefruit juice, halibut, milk, oat bran, potatoes (with skin), salmon, spinach, and tuna should be avoided.

For patients at low or no risk of developing digitalis toxicity, intravenous calcium gluconate may be administered. Additionally, intravenous administration of a 10% dextrose solution containing 10-20 units of crystalline insulin per 1,000 mL at a rate of 300-500 mL/hr can be beneficial. If acidosis is present, correction with intravenous sodium bicarbonate is recommended. In severe cases, hemodialysis or peritoneal dialysis may be necessary. While exchange resins can be utilized, they should not be relied upon as the sole treatment for acute hyperkalemia.

It is important to note that lowering potassium levels too rapidly in patients taking digitalis can lead to digitalis toxicity. Furthermore, in patients with impaired potassium excretion mechanisms, such as those with chronic renal failure or severe myocardial damage, the administration of potassium citrate can precipitate hyperkalemia and potentially fatal cardiac arrest. Therefore, the use of potassium citrate in these populations should be avoided.

Nonclinical Toxicology

Animal reproduction studies have not been conducted to evaluate the teratogenic potential of potassium citrate. Therefore, it remains unknown whether potassium citrate can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. Potassium citrate should be administered to pregnant women only if clearly needed.

Regarding non-teratogenic effects, the normal potassium ion concentration in human milk is approximately 13 mEq/L. However, it is not known if potassium citrate influences this concentration. Consequently, potassium citrate should be given to breastfeeding women only if clearly needed.

No specific details are available concerning nonclinical toxicology or animal pharmacology and toxicology.

Postmarketing Experience

No postmarketing experience details are available in the provided data.

Patient Counseling

Patients should be advised to take each dose of the medication without crushing, chewing, or sucking the tablet to ensure proper absorption and effectiveness. It is crucial for patients to take this medicine only as directed, particularly if they are also using diuretics and digitalis preparations, as this can affect the medication's efficacy and safety.

Patients should be encouraged to communicate with their healthcare provider if they experience any difficulty swallowing the tablets or if they feel that the tablet is sticking in their throat. Additionally, patients must be informed to seek immediate medical attention if they notice tarry stools or any other signs of gastrointestinal bleeding, as these may indicate serious side effects.

Healthcare providers should also explain that regular blood tests and electrocardiograms will be performed by the doctor to monitor the patient's safety while on this medication. This ongoing assessment is essential to ensure the patient's health and the medication's effectiveness.

Storage and Handling

The product is supplied in a tight container and should be stored at a temperature range of 20° to 25°C (68° to 77°F). Excursions outside this range are permissible, provided they remain between 15° and 30°C (59° and 86°F), in accordance with USP controlled room temperature guidelines.

Additional Clinical Information

No further data are available.

FDA Insert (PDF)

This document is the official FDA-approved prescribing information for Potassium Citrate as submitted by Strides Pharma Inc.. It includes detailed information about indications, dosage, contraindications, warnings, and clinical pharmacology.

View full prescribing information (PDF)